Zhenlin Ju

This study shows that BRAFV600E-driven lung cancer requires ERBB receptor signaling via ligand-mediated activation, and combined inhibition of BRAFV600E and ERBB improves therapeutic outcomes.

This study identifies an estrogen receptor signaling program in HR+ breast cancer that suppresses immune responses by reducing T cell infiltration and HLA expression, suggesting therapeutic targets to enhance immunogenicity.

The paper compiles protein response data from cancer cell lines to drug perturbations, showing improved drug sensitivity prediction and building a protein-drug connectivity map with an accessible data portal.